Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Healthy Extracts (HYEX) Cash & Equivalents (2016 - 2025)

Healthy Extracts filings provide 11 years of Cash & Equivalents readings, the most recent being $146935.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 31.17% to $146935.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $146935.0, a 31.17% increase, with the full-year FY2025 number at $146935.0, up 31.17% from a year prior.
  • Cash & Equivalents hit $146935.0 in Q4 2025 for Healthy Extracts, down from $189452.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $286939.0 in Q2 2021 to a low of $19441.0 in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $116968.0 (2021), compared with a mean of $136175.8.
  • Biggest five-year swings in Cash & Equivalents: tumbled 70.44% in 2022 and later skyrocketed 476.2% in 2024.
  • Healthy Extracts' Cash & Equivalents stood at $222098.0 in 2021, then tumbled by 70.44% to $65651.0 in 2022, then plummeted by 70.39% to $19441.0 in 2023, then skyrocketed by 476.2% to $112020.0 in 2024, then soared by 31.17% to $146935.0 in 2025.
  • The last three reported values for Cash & Equivalents were $146935.0 (Q4 2025), $189452.0 (Q3 2025), and $200495.0 (Q2 2025) per Business Quant data.